Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268989 | 0.86 | HSD11B1 (0.37) | HSD11B1RPS6KB1AURKAPARP1ROCK2 | |
| SCHEMBL27757928 | 0.76 | HSD11B1 (0.34) | HSD11B1ALDH1A1PARP1ROCK2ABHD6 | |
| SCHEMBL2264874 | 0.73 | RPS6KB1 (0.50) | RPS6KB1AURKAPARP1ROCK2 | |
| SCHEMBL2269001 | 0.73 | ADRB2 (0.41) | RPS6KB1AURKAPARP1ROCK2 | |
| SCHEMBL2264927 | 0.71 | RPS6KB1 (0.40) | ALDH1A1RPS6KB1AURKAPARP1ROCK2 | |
| SCHEMBL2268996 | 0.69 | RPS6KB1 (0.39) | RPS6KB1AURKAPARP1ROCK2 | |
| SCHEMBL24166883 | 0.67 | HSD11B1 (0.58) | HSD11B1ALDH1A1AOC3 | |
| SCHEMBL3650924 | 0.67 | HSD11B1 (0.58) | HSD11B1ALDH1A1AOC3 | |
| SCHEMBL3441981 | 0.65 | HSD11B1 (0.53) | HSD11B1TLR9TLR8TLR7AOC3 | |
| SCHEMBL309116 | 0.65 | ALDH1A1 (0.54) | HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091920-B1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| CN-101553473-B | Substituted pyrazoles, compositions containing them, methods of production and uses | SANOFI AVENTIS | 2013-06-05 | — | — | CN | disclosed |
| US-8420824-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410286-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| US-7989439-B2 | Substituted pyrazoles, compositions containing these, method of production and use | SANOFI-AVENTIS (FR) | 2011-08-02 | — | — | US | disclosed |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | US | disclosed |
| CN-101553473-A | Substituted pyrazoles, compositions containing them, methods of production and uses | SANOFI AVENTIS (FR) | 2009-10-07 | — | — | CN | disclosed |
| EP-2091920-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | Sanofi-Aventis (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008065282-A2 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | SANOFI-AVENTIS (FR) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237801-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | HSD11B1 922/4885ALDH1A1 354/4885RPS6KB1 422/4885 |
| US-20090291984-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | CYP4B1, ADORA1, CYP1B1 | HSD11B1 756/4885ALDH1A1 242/4885RPS6KB1 310/4885 |
| US-20110237641-A1 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE | ADORA3, ADORA2B, CYP4B1 | HSD11B1 922/4885ALDH1A1 354/4885RPS6KB1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.